Tuesday, December 1, 2009

Ex-CuraGen CEO Tim Shannon joins Canaan Partners

By Galen Moore

Video Gallery

Following the Clean Energy Council Fellows

MHT's Galen Moore: Hiring trends and opportunities

MHT managing editor Rodney Brown on NECN: 22 tech companies give back to community

Related News

UMassOnline brings Masson on as CTO [March 18, 2010]

Children’s Hospital and Genocea Biosciences partner [March 18, 2010]

Babson's Rice joins WPI as first-ever academic dean [March 17, 2010]

Alkermes launches Phase 1 trial for chronic pain drug candidate [March 17, 2010]

ALS Therapy Institute pairs with N.J. biotech [March 17, 2010]

A second former CuraGen Corp. executive has gone to the venture capital side. Canaan Partners announced this morning that former CuraGen CEO Tim Shannon, M.D., has joined the firm’s Westport, Conn. office as a venture partner.

Connecticut Innovations announced on Monday that former CuraGen CFO David Wurzer had joined the quasi-public venture capital nonprofit as a managing director.

According to Canaan’s press release, Shannon will support the firm’s current healthcare portfolio companies and identify new investment opportunities.

CuraGen, a Branford, Conn.-based company using genomics to develop drugs, was acquired by Celldex Therapeutics Inc. last quarter for $94.5 million in stock. In 2007,
Swiss drug maker Roche bought CuraGen business unit 454 Life Sciences Corp. for $154.9 million.